A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

CCI based on various comorbid conditions such as cerebrovascular disease, chronic pulmonary disease, congestive heart failure, dementia, mild/moderate diabetes, diabetes with chronic complications, hemiplegia/paraplegia, HIV, mild liver disease, moderate/severe liver disease, malignancy, metastatic solid tumor, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease, rheumatologic disease was reported. CCI score range was from 0 to 33, where 0= low comorbid condition and 33= high comorbid condition, higher scores indicated more comorbidity. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

CCI based on various comorbid conditions such as cerebrovascular disease, chronic pulmonary disease, congestive heart failure, dementia, mild/moderate diabetes, diabetes with chronic complications, hemiplegia/paraplegia, human immunodeficiency virus(HIV), mild liver disease, moderate/severe liver disease, malignancy, metastatic solid tumor, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease, rheumatologic disease was reported. CCI score range was from 0 to 33, where 0= low comorbid condition and 33= high comorbid condition, higher scores indicated more comorbidity. Index date was the date of first COVID-19 diagnosis. Data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Estimated sum of wages associated with absence days was calculated as daily wage multiplied by absence days was reported PPPM in this outcome measure. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. Outcome measure was planned to be reported for matched participants(treated and untreated) who were eligible for absence. N=participants evaluable for outcome measure and numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence numbers are different from unmatched population (actual enrolled population).

Estimated sum of wages associated with absence days LTD claim was calculated as 70 percent (%) of daily wage multiplied by LTD days was reported PPPM in this outcome measure. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. Outcome measure was planned to be reported for matched participants(treated and untreated)who were eligible for LTD. N=participants evaluable for this outcome measure and numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence numbers are different from unmatched population (actual enrolled population).

Estimated sum of wages associated with absence days STD claim was calculated as 70 percentage (%) of daily wage multiplied by STD days was reported PPPM in this outcome measure. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. Outcome measure was planned to be reported for matched participants(treated and untreated)who were eligible for STD. N=participants evaluable for this outcome measure and numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence numbers are different from unmatched population (actual enrolled population).

Duration of follow-up was defined as number of months from (and including) the index date to the end of participants variable-length follow-up period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Duration of follow-up was defined as number of months from (and including) the index date to the end of participants variable-length follow-up period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

ECI was a measure of comorbidity based on ICD-10 codes. ECI score range was from 0-30. A higher score indicated more comorbidity. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

ECI was a measure of comorbidity based on ICD-10 codes. ECI score range was from 0-30. A higher score indicated more comorbidity. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

In this outcome measure mean number of absence days PPPM was reported. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. Outcome measure was planned to be reported for matched participants(treated and untreated) who were eligible for absence. N=participants evaluable for outcome measure and numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence numbers are different from unmatched population (actual enrolled population).

In this outcome measure mean number of LTD days PPPM was reported. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. Outcome measure was planned to be reported for matched participants(treated and untreated)who were eligible for LTD. N=participants evaluable for this outcome measure and numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence numbers are different from unmatched population (actual enrolled population).

In this outcome measure mean number of STD days PPPM was reported. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. Outcome measure was planned to be reported for matched participants(treated and untreated) who were eligible for STD.N=participants evaluable for this outcome measure and numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence numbers are different from unmatched population (actual enrolled population).

High risk conditions included cancer, cerebrovascular or peripheral vascular disease, chronic lung disease, chronic liver disease, cystic fibrosis, dementia, diabetes, disability, heart conditions, HIV, hypertension, immunocompromised state (primary immunodeficiencies, prolonged use of corticosteroids or other immunosuppressive medications, and other immunocompromised state), mental health conditions (mood disorder or schizophrenia), overweight or obesity, physical inactivity, pregnancy(current or recent), sickle cell disease or thalassemia, smoking (current or former), solid organ or blood stem cell transplant, substance use disorder, tuberculosis. Index date=date of first COVID-19 diagnosis. Data was reported for matched participants, they were further sub-grouped on basis of outcome of COVID-19: eligible for absence from work, short term disability, long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

High risk conditions included cancer, cerebrovascular or peripheral vascular disease, chronic lung disease, chronic liver disease, cystic fibrosis, dementia, diabetes, disability, heart conditions, HIV, hypertension, immunocompromised state(primary immunodeficiencies, prolonged use of corticosteroids or other immunosuppressive medications, and other immunocompromised state), mental health conditions(mood disorder or schizophrenia), overweight or obesity, physical inactivity, pregnancy(current or recent), sickle cell disease or thalassemia, smoking (current or former), solid organ or blood stem cell transplant, substance use disorder, tuberculosis. Index date=date of first COVID-19 diagnosis. Data was reported for unmatched participants, they were further sub-grouped on basis of outcome of COVID-19: eligible for absence from work, short term disability, long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Age group was categorized into following categories: 18-29 years, 30-39 years, 40-49 years, 50-64 years and 65-74 years. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Age group was categorized into following categories: 18-29 years, 30-39 years, 40-49 years, 50-64 years and 65-74 years. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Comorbidities were categorized into following categories: cancer (current or history of), cardio/cerebrovascular disease, chronic kidney disease, chronic liver disease, diabetes mellitus, immunocompromised status, lung disease or tuberculosis, neurodevelopmental disorder/complex condition, overweight/obesity or smoking and pregnancy. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. Participant can have more than 1 comorbidity.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Comorbidities were categorized into following categories: cancer (current or history of), cardio/cerebrovascular disease, chronic kidney disease, chronic liver disease, diabetes mellitus, immunocompromised status, lung disease or tuberculosis, neurodevelopmental disorder/complex condition, overweight/obesity or smoking and pregnancy. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. Participant can have more than 1 comorbidity.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Number of participants with \>=1 claim for a COVID-19 vaccination during the pre-period was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Number of participants with \>=1 claim for a COVID-19 vaccination during the pre-period was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Industry type was categorized into following categories: finance/insurance/real estate, manufacturing (durable/non-durable goods), retail trade, services, transportation/communications/utilities and other. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Industry type was categorized into following categories: finance/insurance/real estate, manufacturing (durable/non-durable goods), retail trade, services, transportation/communications/utilities and other. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Insurance plan type was categorized into following categories: comprehensive/indemnity, EPO/PPO, POS with or without capitation, HMO, CDHP/HDHP and missing/unknown. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Insurance plan type was categorized into following categories: comprehensive/indemnity, exclusive/preferred provider organization (EPO/PPO), point of service capitation (POS) with or without capitation, health maintenance organization (HMO), consumer driven/ high-deductible health plan (CDHP/HDHP) and missing/unknown. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Payer type was categorized as: commercial and medicare. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Payer type was categorized as: commercial and medicare. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Quarter of index year was categorized into following categories: Q4 2021, Q1 2022, Q2 2022, Q3 2022 and Q4 2022. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Quarter of index year was categorized into following categories: Q4 2021, Q1 2022, Q2 2022, Q3 2022 and Q4 2022. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Reasons for LTD were classified as COVID-19 related or non-COVID-19 related or missing/unknown. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. Outcome measure was planned to be reported for matched participants(treated and untreated)who were eligible for LTD. N=participants evaluable for this outcome measure and numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence numbers are different from unmatched population (actual enrolled population).

Reasons for STD were classified as COVID-19 related or non-COVID-19 related or missing/unknown. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. Outcome measure was planned to be reported for matched participants(treated and untreated)who were eligible for STD. N=participants evaluable for this outcome measure and numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence numbers are different from unmatched population (actual enrolled population).

Region of residence was categorized into following categories: Northeast, North Central, South, West and other/ missing. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Region of residence was categorized into following categories: Northeast, North Central, South, West, and other/ missing. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Sex was categorized as: female and male. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Sex was categorized as: female and male. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Absence days was reported by absence type: sick, disability and recreational absence. Sick, disability and recreational absence were the leaves which participants took during the study period. Sick absence referred to the time away from work due to an employee's own illness or medical condition, this may be also used for bereavement, caring for a family member with a serious health condition, adoption-related medical needs. Disability absence was recorded when an employee was unable to work due to a short-term or long-term disability. Recreational absence referred to the time off taken for non-medical, personal reasons, such as vacation, personal leave, leisure, or wellness days. Index date was the date of first COVID-19 diagnosis. One participant may have more than one type of absence claim.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. Outcome measure was planned to be reported for matched participants(treated and untreated) who were eligible for absence. N=participants evaluable for outcome measure and numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence numbers are different from unmatched population (actual enrolled population).

Number of participants with presence of any LTD claim was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated) who were eligible for LTD. Here, N signifies the numbers which were matched /adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Number of participants with presence of any STD claim was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated) who were eligible STD. Here, N=numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Prior ER visit indicates participants who had one or more ER visits in pre-period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed (N) signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Prior ER visit indicates participants who had one or more ER visits in pre-period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Prior hospitalization indicated participants who had one or more inpatients visits in the pre-period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).

Prior hospitalization indicated participants who had one or more inpatients visits in the pre-period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated).

Number of participants with presence of any absence records was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis.

Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

Population: Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated) who were eligible for absence from work due to COVID-19. Here, N=numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population).